Every investor in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership.

Researchers have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these ...

In the development of biopharmaceutical products, the characterization of thermal stability is a critical step for optimizing monoclonal antibodies (mAbs) and their formulations. A standard technique ...

National Institute of Standards and Technology (NIST) researchers at the Institute for Bioscience and Biotechnology Research (IBBR) have demonstrated the most precise method yet to measure the ...

The analysis of the operational expenses has been a key factor in the revised valuation, indicating a more efficient cost structure for Y-mAbs. Looking ahead, BMO Capital expressed a positive outlook ...

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today introduced a new cation exchange column line with specialized consumables to simplify and improve the characterization and ...

Traditional biologics, which are predominantly monoclonal antibodies (mAbs), are continuing to see strong market demand, and the pipeline for mAb development is also robust. While the ...

The Outperform rating was reiterated based on the company's current spending trajectory, which has influenced BMO's valuation of the drug. The analysis of the operational expenses has been a key ...